Yamaguchi Akio, Goi Takanori, Yu Jiren, Hirono Yasuo, Ishida Makoto, Iida Atsushi, Kimura Toshihisa, Takeuchi Kazuo, Katayama Kanji, Hirose Kazuo
First Department of Surgery, School of Medicine, Fukui Medical, University, Fukui, Japan.
J Surg Oncol. 2002 Apr;79(4):230-5. doi: 10.1002/jso.10082.
Variants of CD44 have been proposed to be important in promoting tumor progression and metastasis. We attempted to determine the expression of CD44v6 product in advanced gastric cancer and to evaluate its prognostic value.
The expression of CD44v6 was analyzed immunohistochemically in advanced gastric cancers using monoclonal antibody, 44-2V. We investigated the relationship between CD44v6 expression and prognosis in 201 gastric cancer patients.
Ninety-five (47.3%) of 201 cancer tissues expressed CD44v6. The expression of CD44v6 protein was significantly higher in differentiated, adenocarcinoma than in diffuse type carcinoma. The CD44v6-positive cancers were more frequently associated with hematogenous metastasis. There was no significant correlation between CD44v6 immunoreactivity, and prognosis among the combined cases. Among patients with differentiated adenocarcinoma, however, the prognosis was significantly poorer in patients with CD44v6-positive tumors than in those with CD44v6-negative tumors.
CD44v6 protein may have an important role in hematogenous metastasis, and may be a biologic marker of prognostic significance in differentiated type gastric cancers.
CD44变体被认为在促进肿瘤进展和转移方面具有重要作用。我们试图确定CD44v6产物在进展期胃癌中的表达情况，并评估其预后价值。
使用单克隆抗体44-2V对进展期胃癌组织进行免疫组织化学分析，检测CD44v6的表达。我们对201例胃癌患者中CD44v6表达与预后的关系进行了研究。
201例癌组织中有95例（47.3%）表达CD44v6。CD44v6蛋白在分化型腺癌中的表达显著高于弥漫型癌。CD44v6阳性的癌症更常发生血行转移。在所有病例中，CD44v6免疫反应性与预后之间无显著相关性。然而，在分化型腺癌患者中，CD44v6阳性肿瘤患者的预后明显差于CD44v6阴性肿瘤患者。
CD44v6蛋白可能在血行转移中起重要作用，并且可能是分化型胃癌中具有预后意义的生物学标志物。
